Administration of the p38 MAPK inhibitor SB203580 affords brain protection with a wide therapeutic window against focal ischemic insult. [electronic resource]
Producer: 20030908Description: 537-44 p. digitalISSN:- 0360-4012
- Animals
- Anti-Inflammatory Agents, Non-Steroidal -- therapeutic use
- Astrocytes -- drug effects
- Blotting, Western -- methods
- Brain -- drug effects
- Brain Infarction -- metabolism
- Cyclooxygenase 2
- Cytokines -- genetics
- Disease Models, Animal
- Gene Expression Regulation -- drug effects
- Imidazoles -- therapeutic use
- Immunohistochemistry -- methods
- Infarction, Middle Cerebral Artery -- physiopathology
- Isoenzymes -- genetics
- Lectins -- metabolism
- Male
- Microglia -- drug effects
- Mitogen-Activated Protein Kinase 14
- Mitogen-Activated Protein Kinases -- antagonists & inhibitors
- Neurologic Examination
- Nitric Oxide Synthase -- genetics
- Nitric Oxide Synthase Type II
- Prostaglandin-Endoperoxide Synthases -- genetics
- Pyridines -- therapeutic use
- RNA, Messenger -- biosynthesis
- Rats
- Rats, Sprague-Dawley
- Reverse Transcriptase Polymerase Chain Reaction -- methods
- Tetrazolium Salts -- metabolism
- Time Factors
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.